These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32312777)

  • 21. Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.
    Carena AA; Stryjewski ME
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):577-592. PubMed ID: 32449440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.
    Douros A; Grabowski K; Stahlmann R
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1849-59. PubMed ID: 26457865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tedizolid: new data and experiences for clinical practice.
    Salavert Lletí M; García-Bustos V; Morata Ruiz L; Cabañero-Navalon MD
    Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):22-25. PubMed ID: 34598418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tedizolid: a service evaluation in a large UK teaching hospital.
    York JA; Adams K; Cullen L; Delahay J; Ivan M; Lillie PJ; MacLachlan L; Barlow G
    Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):397-405. PubMed ID: 32851509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs.
    Benavent E; Morata L; Escrihuela-Vidal F; Reynaga EA; Soldevila L; Albiach L; Pedro-Botet ML; Padullés A; Soriano A; Murillo O
    Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33429902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tedizolid population pharmacokinetics, exposure response, and target attainment.
    Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
    Rybak JM; Marx K; Martin CA
    Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers.
    Fang E; Muñoz KA; Prokocimer P
    Am J Ther; 2017; 24(2):e227-e233. PubMed ID: 27941424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.
    Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tedizolid for treatment of acute bacterial skin and skin structure infections.
    Hui Y; Xiaoju L
    Expert Rev Anti Infect Ther; 2015; 13(9):1051-60. PubMed ID: 26211946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
    Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of in vitro activity of tedizolid and linezolid against Mycobacterium avium complex.
    Marfil E; Ruiz P; Martínez-Martínez L; Causse M
    J Glob Antimicrob Resist; 2022 Sep; 30():395-398. PubMed ID: 35863729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombocytopenia with Tedizolid and Linezolid.
    Lee EY; Caffrey AR
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections.
    Gras J
    Drugs Today (Barc); 2014 Nov; 50(11):729-37. PubMed ID: 25525633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials.
    Moran GJ; De Anda C; Das AF; Green S; Mehra P; Prokocimer P
    Infect Dis Ther; 2018 Dec; 7(4):509-522. PubMed ID: 30242736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting.
    Abad L; Tafani V; Tasse J; Josse J; Chidiac C; Lustig S; Ferry T; Diot A; Laurent F; Valour F
    J Antimicrob Chemother; 2019 Mar; 74(3):625-632. PubMed ID: 30517641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of tedizolid for the treatment of MRSA infections.
    Hall RG; Smith WJ; Putnam WC; Pass SE
    Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.
    Flanagan S; McKee EE; Das D; Tulkens PM; Hosako H; Fiedler-Kelly J; Passarell J; Radovsky A; Prokocimer P
    Antimicrob Agents Chemother; 2015 Jan; 59(1):178-85. PubMed ID: 25331703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of tedizolid in skin and soft tissue infections.
    Bouza E; Muñoz P; Burillo A
    Curr Opin Infect Dis; 2018 Apr; 31(2):131-140. PubMed ID: 29346119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.